ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1036

Ocular Involvement and Treatment in Sarcodosis. Study of 41 Patients of a Series of 383 Patients from a Single University Hospital
Abstract Number: 1044

Ocular Manifestations in Inflammatory Bowel Disease. Study of 1442 Patients from a Single Referral Center
Abstract Number: 1043

Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center
Abstract Number: 2011

Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Abstract Number: 1921

Ongoing Vascular 18F-FDG Uptake Despite Clinical Remission in Patients Receiving Tocilizumab for Large Vessel Vasculitis-Giant Cell Arteritis: Single Universitary Center Experience of 30 Patients
Abstract Number: PP06

Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope
Abstract Number: 1566

Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
Abstract Number: 1281

Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Abstract Number: 0402

Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis
Abstract Number: 1553

Optical Tomography Can Accurately Diagnose Lupus Arthritis
Abstract Number: 0833

Optimized Treatment of Biological Disease Modifying Drugs in Routine Clinical Practice: Survival Study and Analysis of Patient Characteristics
Abstract Number: 1021

Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Abstract Number: 0389

Organ Specific Treatment Patterns of a Real-World, Electronic Health Record Cohort of Patients with Systemic Sclerosis
Abstract Number: 0931

Oropharyngeal Dysfunction in Patients with Systemic Sclerosis – Results of a Monocentric Clinical Study
Abstract Number: 1122

Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].